Weather , , 0°C

Graft-versus-host disease (GvHD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

 Breaking News
  • No posts were found

Graft-versus-host disease (GvHD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

May 28
22:02 2021
Graft-versus-host disease (GvHD) Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Graft-versus-host disease (GvHD)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Graft-versus-host disease (GvHD), historical and forecasted epidemiology as well as the Graft-versus-host disease (GvHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Graft-versus-host disease (GvHD)-Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Graft-versus-host disease (GvHD)–Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Graft-versus-host disease (GvHD), historical and forecasted epidemiology as well as the Graft-versus-host disease (GvHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  • In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting increased cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.
  • Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 cases in 2020. 
  • In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per DelveInsight’s analysis, around 3,278 cases of cGvHD were treated in first-line in the United States in 2020.

Key benefits of the report:

1.The Graft-versus-host disease (GvHD) market report covers a descriptive overview and comprehensive insight of the Graft-versus-host disease (GvHD) epidemiology and Graft-versus-host disease (GvHD) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.The Graft-versus-host disease (GvHD) market report provides insights into the current and emerging therapies.

3.Graft-versus-host disease (GvHD) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4.The Graft-versus-host disease (GvHD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft-versus-host disease (GvHD) market.

Request for sample pages: https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

Graft-versus-host disease (GvHD): Overview

Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem Cell Transplantation).

The two main types of GvHD are acute GvHD and chronic GvHD. Other than this, GvHD is classified into other types, namely: classic acute GvHD, persistent, recurrent, late-onset acute GvHD, classic chronic GvHD, and overlap syndrome and de novo chronic GvHD. Patients who get acute GvHD have a 50% chance of developing chronic GvHD.

Acute GvHD (aGvHD) might occur once the donor’s cells have engrafted in the transplant recipient and have been observed to affect skin, liver, or gastrointestinal tract. Symptoms might appear within 3 months after the transplant.

The key players involved in the Graft-versus-host disease (GvHD) market:

1. CSL Behring

2. Medac

3. ElsaLys Biotech

4. Kadmon Therapeutics

5. Biogen

The launch of the emerging therapies is expected to significantly impact the Graft-versus-host disease (GvHD) treatment scenario in the upcoming years:-

Drug covered

  1. Lecanemab (BAN2401) 
  2. Obnitix
  3. Inolimomab
  4. KD025 (Belumosudil) 
  5. Natalizumab

Request a free sample report @https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Graft-versus-host disease (GvHD) Patient Share (%) Overview at a Glance

5. Graft-versus-host disease (GvHD) Market Overview at a Glance

6. Graft-versus-host disease (GvHD) Disease Background and Overview

7. Graft-versus-host disease (GvHD) Epidemiology and Patient Population

8. Country-Specific Patient Population of Graft-versus-host disease (GvHD) 

9. Graft-versus-host disease (GvHD) Current Treatment and Medical Practices

10. Unmet Needs

11. Graft-versus-host disease (GvHD) Emerging Therapies

12. Graft-versus-host disease (GvHD) Market Outlook

13. Country-Wise Graft-versus-host disease (GvHD) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Graft-versus-host disease (GvHD) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Graft-versus-host disease (GvHD)-Pipeline Insights, 2021

“Graft-versus-host disease (GvHD)-Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Graft-versus-host disease (GvHD) market. A detailed picture of the Graft-versus-host disease (GvHD) pipeline landscape is provided, which includes the disease overview and Graft-versus-host disease (GvHD) treatment guidelines.

Graft-versus-host disease (GvHD)-Epidemiology Forecast to 2030

DelveInsight’s ‘Graft-versus-host disease (GvHD)-Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Graft-versus-host disease (GvHD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spawere n, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

June 2021
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  

Categories